ADA, Xeris partner on glucagon campaign
By HME News Staff
Updated 2:08 PM CST, Wed January 22, 2025
CHICAGO and ARLINGTON, Va. - The American Diabetes Association and a national supporter, Xeris Pharmaceuticals, have formed a multi-year strategic partnership to reinforce the importance of prescribing glucagon for all individuals with diabetes who are treated with insulin and/or insulin secretagogues or those at high risk of hypoglycemia. "Severe hypoglycemia is life-threatening, and people with diabetes on blood glucose-lowering medication are at risk for hypoglycemia,” said Charles Henderson, ADA CEO. “Thus, we must act with urgency to educate people about the importance of having a treatment plan in place that includes having glucagon on hand. Through this important partnership, we can save lives by ensuring individuals with diabetes who are treated with insulin have access to glucagon, preferably a ready-to-use formulation, so they can make a plan and be ready." Hypoglycemia is conservatively responsible for more than 202,000 emergency department visits annually with approximately 25% being admitted to the hospital. The ADA, with support from Xeris, seeks to rectify the low rates of appropriate glucagon prescriptions by developing education materials and training resources for health care professionals and people living with diabetes, as well as through a national awareness campaign, to educate people on who is at risk for severe hypoglycemia and should have glucagon, preferably ready-to-use, as a safety net.
Comments